Shu Pei, Wang Fang, Wang Xin
Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2025 May 2;16:1536689. doi: 10.3389/fimmu.2025.1536689. eCollection 2025.
There is currently no established standard treatment for patients with metastatic hepatocellular carcinoma after resistance to tyrosine kinase inhibitors. Given that radiotherapy can reprogram the tumor microenvironment and convert "cold" tumors into "hot" tumors, combining radiotherapy with immunotherapy shows significant potential. In this case, we present a male patient with HBV-related metastatic hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombosis. The patient achieved abscopal effect with a progression-free survival of 10 months and an overall survival of 21 months with the combination of anti-PD-1 therapy and stereotactic body radiotherapy (SBRT) as third-line treatment. This combination therapy demonstrates relative efficacy and favorability in treating HBV-related advanced HCC.
目前，对于对酪氨酸激酶抑制剂耐药的转移性肝细胞癌患者，尚无既定的标准治疗方法。鉴于放射治疗可重新编程肿瘤微环境并将“冷”肿瘤转化为“热”肿瘤，放射治疗与免疫治疗联合显示出巨大潜力。在此病例中，我们报告一名患有乙肝病毒相关转移性肝细胞癌（HCC）并伴有门静脉肿瘤血栓形成的男性患者。该患者接受抗程序性死亡蛋白1（PD-1）治疗与立体定向体部放疗（SBRT）联合作为三线治疗，实现了远隔效应，无进展生存期为10个月，总生存期为21个月。这种联合治疗在治疗乙肝病毒相关晚期HCC方面显示出相对疗效和优势。
